Ignite Creation Date:
2024-05-06 @ 3:59 AM
Last Modification Date:
2024-10-26 @ 11:42 AM
Study NCT ID:
NCT02424669
Status:
UNKNOWN
Last Update Posted:
2015-11-17
First Post:
2015-04-20
Brief Title:
Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives a Translational Pilot Study Among ALS Patients
Sponsor:
Assistance Publique Hopitaux De Marseille
Organization:
Assistance Publique Hopitaux De Marseille
Study Overview
Official Title:
Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives a Translational Pilot Study Among ALS Patients
Status:
UNKNOWN
Status Verified Date:
2015-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Amyotrophic Lateral Sclerosis ALS is the most common motor neuron diseases It is considered as a rare disease with a prevalence of about 8 per 100000 persons Initiating in mid-life by progressive paralysis it evolves rapidly into a generalized muscle wasting that leads irrevocably to death within 2 or 5 years of clinical onset
Since there is no cure for ALS the management of the disease is supportive and palliative Riluzole is the only drug that has been shown to extend survival by about three months The identification of biomarkers sensitive to the progression of the disease might enhance the diagnostic and provide new drug targets
Dysfunction of the immune system is a pathological hallmark of ALS Increased levels of interferon gamma IFNgamma were found in the serum and cerebrospinal fluid CSF of ALS patients However the cell origin as well as the pathogenic influence of this peripheral source of IFNg is unknown Thus IFNgamma might have a role in the pathogenic process of ALS and might be a potential biomarker of the disease
Since there is no cure for ALS the management of the disease is supportive and palliative Riluzole is the only drug that has been shown to extend survival by about three months The identification of biomarkers sensitive to the progression of the disease might enhance the diagnostic and provide new drug targets
Dysfunction of the immune system is a pathological hallmark of ALS Increased levels of interferon gamma IFNgamma were found in the serum and cerebrospinal fluid CSF of ALS patients However the cell origin as well as the pathogenic influence of this peripheral source of IFNg is unknown Thus IFNgamma might have a role in the pathogenic process of ALS and might be a potential biomarker of the disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| RCAPHM15_0132 | REGISTRY | Assistance Publique Hôpitaux Marseille | None |